Business

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

articleSuzhou Zelgen Biopharmaceuticals Co. Ltd. Class AApril 13, 20263/news/announcement-on-voluntary-disclosure-of-results-of-the-phase-iii-clinical-trial-of-gecacitinib-hydrochloride-tablets-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-reaching-the-primary-efficacy-endpoint
Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A